Effect of interferon-alpha therapy in a patient with common variable immunodeficiency and chronic Epstein-Barr virus infection. 1995

R Toraldo, and M D'Avanzo, and C Tolone, and G Canino, and F Iafusco, and L D Notarangelo, and A Ugazio, and C Cirillo
Dipartimento di Pediatrica, II Università di Napoli, Italy.

We report an 18-year-old boy with common variable immunodeficiency who presented with splenomegaly as well as left axillary and lateral cervical lymphadenopathy. Main laboratory investigations showed severe thrombocytopenia. Epstein-Barr virus (EBV) DNA was detected in the patient's throat-washing specimens and lymph node biopsy. Lymphocytes from the lymph node biopsy were also positive for EBV nuclear antigen. Serology for EBV and cytomegalovirus was negative. A therapeutic attempt with acyclovir did not influence the course of infection. Six months' treatment with human lymphoblastoid interferon-alpha (IFN alfa) brought about the normalization of clinical and hematologic conditions. Detection on throat-washing specimens carried out 1 year after therapy was negative. Our preliminary experience suggests that human lymphoblastoid IFN-alpha is a valid alternative in therapy of immunodeficient EB virus-infected patients.

UI MeSH Term Description Entries
D008297 Male Males
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004854 Herpesvirus 4, Human The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies. Burkitt Herpesvirus,Burkitt Lymphoma Virus,E-B Virus,EBV,Epstein-Barr Virus,Human Herpesvirus 4,Infectious Mononucleosis Virus,Burkitt's Lymphoma Virus,HHV-4,Herpesvirus 4 (gamma), Human,Burkitts Lymphoma Virus,E B Virus,E-B Viruses,Epstein Barr Virus,Herpesvirus, Burkitt,Infectious Mononucleosis Viruses,Lymphoma Virus, Burkitt,Mononucleosis Virus, Infectious,Mononucleosis Viruses, Infectious
D006566 Herpesviridae Infections Virus diseases caused by the HERPESVIRIDAE. Herpesvirus Infections,B Virus Infection,Infections, Herpesviridae,Infections, Herpesvirus,B Virus Infections,Herpesviridae Infection,Herpesvirus Infection,Infection, B Virus,Infection, Herpesviridae,Infection, Herpesvirus,Infections, B Virus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D014412 Tumor Virus Infections Infections produced by oncogenic viruses. The infections caused by DNA viruses are less numerous but more diverse than those caused by the RNA oncogenic viruses. Fibroma, Shope,Papilloma, Shope,Infections, Tumor Virus,Infection, Tumor Virus,Shope Fibroma,Shope Papilloma,Tumor Virus Infection
D016898 Interferon-alpha One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways. Interferon Alfa,Interferon, Leukocyte,Interferon, Lymphoblast,alpha-Interferon,IFN-alpha D,IFN-alpha5,Interferon alpha-1,Interferon alpha-17,Interferon alpha-4,Interferon alpha-5,Interferon alpha-7,Interferon alpha-88,Interferon alpha-J,Interferon alpha-T,Interferon alpha4,Interferon alpha5,Interferon, Lymphoblastoid,Interferon, alpha,LeIF I,LeIF J,Leif D,IFN alpha D,IFN alpha5,Interferon alpha,Interferon alpha 1,Interferon alpha 17,Interferon alpha 4,Interferon alpha 5,Interferon alpha 7,Interferon alpha 88,Interferon alpha J,Interferon alpha T,Leukocyte Interferon,Lymphoblast Interferon,Lymphoblastoid Interferon,alpha Interferon
D017074 Common Variable Immunodeficiency Heterogeneous group of immunodeficiency syndromes characterized by hypogammaglobulinemia of most isotypes, variable B-cell defects, and the presence of recurrent bacterial infections. Immunodeficiency, Common Variable,Common Variable Hypogammaglobulinemia,Common Variable Immune Deficiency,Hypogammaglobulinemia, Acquired,Immunoglobulin Deficiency, Late-Onset,Acquired Hypogammaglobulinemia,Acquired Hypogammaglobulinemias,Common Variable Hypogammaglobulinemias,Common Variable Immunodeficiencies,Deficiencies, Late-Onset Immunoglobulin,Deficiency, Late-Onset Immunoglobulin,Hypogammaglobulinemia, Common Variable,Hypogammaglobulinemias, Acquired,Hypogammaglobulinemias, Common Variable,Immunodeficiencies, Common Variable,Immunoglobulin Deficiencies, Late-Onset,Immunoglobulin Deficiency, Late Onset,Late-Onset Immunoglobulin Deficiencies,Late-Onset Immunoglobulin Deficiency,Variable Hypogammaglobulinemia, Common,Variable Hypogammaglobulinemias, Common

Related Publications

R Toraldo, and M D'Avanzo, and C Tolone, and G Canino, and F Iafusco, and L D Notarangelo, and A Ugazio, and C Cirillo
January 1997, Journal of clinical & laboratory immunology,
R Toraldo, and M D'Avanzo, and C Tolone, and G Canino, and F Iafusco, and L D Notarangelo, and A Ugazio, and C Cirillo
May 1987, Annals of internal medicine,
R Toraldo, and M D'Avanzo, and C Tolone, and G Canino, and F Iafusco, and L D Notarangelo, and A Ugazio, and C Cirillo
January 2022, Frontiers in immunology,
R Toraldo, and M D'Avanzo, and C Tolone, and G Canino, and F Iafusco, and L D Notarangelo, and A Ugazio, and C Cirillo
August 2004, International journal of hematology,
R Toraldo, and M D'Avanzo, and C Tolone, and G Canino, and F Iafusco, and L D Notarangelo, and A Ugazio, and C Cirillo
January 1992, Journal of clinical & laboratory immunology,
R Toraldo, and M D'Avanzo, and C Tolone, and G Canino, and F Iafusco, and L D Notarangelo, and A Ugazio, and C Cirillo
January 1998, Journal of pediatric hematology/oncology,
R Toraldo, and M D'Avanzo, and C Tolone, and G Canino, and F Iafusco, and L D Notarangelo, and A Ugazio, and C Cirillo
January 1997, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
R Toraldo, and M D'Avanzo, and C Tolone, and G Canino, and F Iafusco, and L D Notarangelo, and A Ugazio, and C Cirillo
January 2005, Pediatric nephrology (Berlin, Germany),
R Toraldo, and M D'Avanzo, and C Tolone, and G Canino, and F Iafusco, and L D Notarangelo, and A Ugazio, and C Cirillo
October 2023, Open forum infectious diseases,
R Toraldo, and M D'Avanzo, and C Tolone, and G Canino, and F Iafusco, and L D Notarangelo, and A Ugazio, and C Cirillo
April 1995, Leukemia & lymphoma,
Copied contents to your clipboard!